REIKO TAPIA: Open Payments
NPI 1972211050 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,540 in 186 payments from 19 companies in 2025. Trend: 2023 $1,513 · 2024 $3,994 · 2025 $4,540
Food & beverage: $4,456Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $872 |
| Janssen Biotech, Inc. | 26 | $703 |
| Intra-Sana Laboratories | 39 | $508 |
| Gilead Sciences, Inc. | 19 | $501 |
| Phathom Pharmaceuticals, Inc. | 11 | $365 |
| Madrigal Pharmaceuticals | 8 | $363 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $281 |
| GENZYME CORPORATION | 15 | $190 |
| Aimmune Therapeutics, Inc. | 4 | $182 |
| Novo Nordisk Inc | 5 | $171 |
Products named: TREMFYA, RELTONE 200 MG, VOQUEZNA, REZDIFFRA, SKYRIZI, XIFAXAN, RINVOQ, DUPIXENT.
Industry payments across NV — which companies pay providers there.
